"The time taken to establish the correct diagnosis is on average about 14 months."
"I have two little children and they deserve a good life and a caring mother. That thought gives me strength."
"We really wish COVID-19 patients would come to the hospital sooner."
AOP Health presents final results from its CONTINUATION-PV study -up to 7.5 years treatment with BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera patients - at EHA 2022 Annual Meeting13. 6. 2022
AOP Health Submits New Drug Application for Landiolol, Seeking Approval in the United States2. 6. 2022
AOP Health opens its Italian base in Pisa20. 5. 2022
Meet Us Globally
World Orphan Drug CongressBoston
Bio-Europe 2022Leipzig, DE
Meet Us in Poland
AOP Health team covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.
Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Health using the link below.
In the field of rare diseases the AOP Health team develops and investigates therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.